{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T03:22:42Z","timestamp":1696389762736},"reference-count":49,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1002\/jps.23184","type":"journal-article","created":{"date-parts":[[2012,5,31]],"date-time":"2012-05-31T20:11:15Z","timestamp":1338495075000},"page":"2621-2634","source":"Crossref","is-referenced-by-count":3,"title":["Dosing Regimen Determination for Juvenile Idiopathic Arthritis: A Review of Studies During Drug Development11Opinions expressed in this manuscript are those of the authors\u2019 and do not reflect the views or policies of the US Food and Drug Administration."],"prefix":"10.1016","volume":"101","author":[{"given":"Ping","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Badrul A.","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Yim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandrahas G.","family":"Sahajwalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.23184_bb0010","first-page":"1520","article-title":"Worldwide prevalence of juvenile arthritis why does it vary so much?","volume":"29","author":"Manners","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1002\/jps.23184_bb0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/jps.23184_bb0020","first-page":"367","article-title":"Juvenile arthritis\u2014Who gets it, where and when? A review of current data on incidence and prevalence","volume":"17","author":"Andersson G\u00e4re","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"10.1002\/jps.23184_bb0025","first-page":"326","article-title":"Medical treatment of juvenile idiopathic arthritis","volume":"31","author":"Horneff","year":"2008","journal-title":"Med Monatsschr Pharm"},{"key":"10.1002\/jps.23184_bb0030","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/berh.2002.0234","article-title":"Advanced therapy for juvenile arthritis","volume":"16","author":"Murray","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1002\/jps.23184_bb0035","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0040","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0045","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0050","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0055","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.296.10.1266","article-title":"Peer-reviewed publication of clinical trials completed for pediatric exclusivity","volume":"296","author":"Benjamin","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/jps.23184_bb0060","first-page":"64","article-title":"Prescribing medications in pediatrics: Concerns regarding FDA approval and pharmacokinetics","volume":"33","author":"Novak","year":"2007","journal-title":"Pediatr Nurs"},{"key":"10.1002\/jps.23184_bb0065","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0889-857X(21)00130-7","article-title":"The immunogenetics of juvenile rheumatoid arthritis","volume":"17","author":"Nepom","year":"1991","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1002\/jps.23184_bb0070","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3109\/03009747709095449","article-title":"Naproxen in the treatment of juvenile rheumatoid arthritis. Metabolism, safety and efficacy","volume":"6","author":"Makela","year":"1977","journal-title":"Acand J Rheumatol"},{"key":"10.1002\/jps.23184_bb0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/ard.38.2.152","article-title":"Naproxen in juvenile chronic polyarthritis","volume":"38","author":"Moran","year":"1979","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/jps.23184_bb0085","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3109\/03009748409111307","article-title":"Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study","volume":"13","author":"Kvien","year":"1984","journal-title":"Scand J Rheumatol"},{"key":"10.1002\/jps.23184_bb0090","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-3476(77)81045-7","article-title":"Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis","volume":"91","author":"Levinson","year":"1977","journal-title":"J Pediatr"},{"key":"10.1002\/jps.23184_bb0095","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0100","author":"US Food and Drug Administration Advisory Committee Meeting Background Document"},{"key":"10.1002\/jps.23184_bb0105","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/art.20860","article-title":"A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis","volume":"52","author":"Ruperto","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1002\/jps.23184_bb0110","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0115","author":"US Food and Drug Administration Advisory Committee Meeting Background Document"},{"key":"10.1002\/jps.23184_bb0120","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0125","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T","article-title":"Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group","volume":"41","author":"van Rossum","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1002\/jps.23184_bb0130","first-page":"360","article-title":"Sulfasalazine therapy for juvenile rheumatoid arthritis","volume":"23","author":"Imundo","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1002\/jps.23184_bb0135","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1056\/NEJM199204163261602","article-title":"Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.\u2013U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group","volume":"326","author":"Giannini","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.23184_bb0140","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F","article-title":"Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis","volume":"43","author":"Woo","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1002\/jps.23184_bb0145","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.23184_bb0150","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/0091270004271945","article-title":"Population pharmacokinetics analysis and simulation of time concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis","volume":"45","author":"Yim","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.23184_bb0155","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.23184_bb0160","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/jps.23184_bb0165","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0170","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1002\/jps.23184_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-008-0123-3","article-title":"Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan","volume":"19","author":"Mori","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1002\/jps.23184_bb0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1185\/03007997509113646","article-title":"Naproxen absorption in children","volume":"3","author":"Ansell","year":"1975","journal-title":"Curr Med Res Opin"},{"key":"10.1002\/jps.23184_bb0185","first-page":"384","article-title":"A once-daily anti-inflammatory drug, oxaprozin, in the treatment of juvenile rheumatoid arthritis","volume":"12","author":"Bass","year":"1985","journal-title":"J Rheumatol"},{"key":"10.1002\/jps.23184_bb0190","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/0091270004267589","article-title":"Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis","volume":"44","author":"Burgos-Vargas","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.23184_bb0195","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0149-2918(99)80050-2","article-title":"Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis","volume":"21","author":"Boni","year":"1999","journal-title":"Clin Ther"},{"key":"10.1002\/jps.23184_bb0200","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-198510040-00001","article-title":"Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid","volume":"10","author":"Klotz","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jps.23184_bb0205","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/cpt1975185part1514","article-title":"Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease","volume":"18","author":"Das","year":"1975","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.23184_bb0210","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","article-title":"Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis","volume":"221","author":"Gubner","year":"1951","journal-title":"Am J Med Sci"},{"key":"10.1002\/jps.23184_bb0215","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00000441-195102000-00008","article-title":"Therapeutic suppression of tissue reactivity. I. Comparison of the effects of cortisone and aminopterin","volume":"221","author":"Gubner","year":"1951","journal-title":"Am J Med Sci"},{"key":"10.1002\/jps.23184_bb0220","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/BF00193703","article-title":"Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics","volume":"47","author":"Albertioni","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.23184_bb0225","first-page":"113","article-title":"High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis","volume":"13","author":"Reiff","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1002\/jps.23184_bb0230","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1002\/jps.23184_bb0235","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0240","author":"US Food and Drug Administration"},{"key":"10.1002\/jps.23184_bb0245","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10928-005-0049-8","article-title":"Population pharmacokinetics of the active metabolite of leflunomide in pediatric subjects with polyarticular course juvenile rheumatoid arthritis","volume":"32","author":"Shi","year":"2005","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1002\/jps.23184_bb0250","first-page":"205","article-title":"Juvenile idiopathic arthritis: Therapies in the 21st century","volume":"65","author":"Haines","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915314775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915314775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T14:39:33Z","timestamp":1642343973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915314775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0022354915314775"],"URL":"https:\/\/doi.org\/10.1002\/jps.23184","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}